NCT00469183 - Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Melasma

Interventions

DRUG

Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%

Apply topically daily for 12 weeks and continue until condition is clear or almost clear for up to 24 weeks; Maintenance phase: Apply topically twice weekly until the end of study (24 weeks) or condition relapses

Trial Locations (2)

75390

University of Texas Southwestern Medical Center of Dallas, Dallas

90036

Vitiligo and Pigmentation Institute of Southern California, Los Angeles